Full Text Journal Articles by
Author Stacey J Adam


Find full text journal articles

Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials.

Timothy G Buchman, Ruxandra Draghia-Akli, Stacey J Adam, Neil R Aggarwal, Joshua P Fessel, Elizabeth S Higgs, Joseph P Menetski, Sarah W Read, Eric A Hughes, ,

Given the urgent need for coronavirus disease 2019 therapeutics, early in the pandemic the Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership rapidly designed a unique therapeutic agent intake and assessment process for candidate treatments of coronavirus disease 2019. These treatments included antivirals, immune modulators, severe acute ... Read more >>

Crit Care Med (Critical care medicine)
[2021, 49(11):1963-1973]

Cited: 0 times

View full text PDF listing >>

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics.

Lisa LaVange, Stacey J Adam, Judith S Currier, Elizabeth S Higgs, Lora A Reineck, Eric A Hughes, Sarah W Read, ,

Working in an unprecedented time frame, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership developed and launched 9 master protocols between 14 April 2020 and 31 May 2021 to allow for the coordinated and efficient evaluation of multiple investigational therapeutic agents for COVID-19. The ACTIV master protocols were ... Read more >>

Ann Intern Med (Annals of internal medicine)
[2021, 174(9):1293-1300]

Cited: 2 times

View full text PDF listing >>


Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.

Kenneth C Anderson, Daniel Auclair, Stacey J Adam, Amit Agarwal, Melissa Anderson, Herve Avet-Loiseau, Mark Bustoros, Jessica Chapman, Dana E Connors, Ajeeta Dash, Alessandra Di Bacco, Ling Du, Thierry Facon, Juan Flores-Montero, Francesca Gay, Irene M Ghobrial, Nicole J Gormley, Ira Gupta, Howard Higley, Jens Hillengass, Bindu Kanapuru, Dickran Kazandjian, Gary J Kelloff, Ilan R Kirsch, Brandon E Kremer, Ola Landgren, Elizabeth D Lightbody, Oliver C Lomas, Sagar Lonial, Maria Victoria Mateos, Rocio Montes de Oca, Lata Mukundan, Nikhil C Munshi, Elizabeth K O'Donnell, Alberto Orfao, Bruno Paiva, Reshma Patel, Trevor J Pugh, Karthik Ramasamy, Jill Ray, Mikhail Roshal, Jeremy A Ross, Caroline C Sigman, Katie L Thoren, Suzanne Trudel, Gary A Ulaner, Nancy Valente, Brendan M Weiss, Elena Zamagni, Shaji K Kumar,

The development of novel agents has transformed the treatment paradigm for multiple myeloma (MM), with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow-based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC).

Helen X Chen, Minkyung Song, Holden T Maecker, Sacha Gnjatic, David Patton, J Jack Lee, Stacey J Adam, Radim Moravec, Xiaole Shirley Liu, Ethan Cerami, James Lindsay, Ming Tang, F Stephen Hodi, Catherine J Wu, Ignacio I Wistuba, Gheath Al-Atrash, Chantale Bernatchez, Sean C Bendall, Stephen M Hewitt, Elad Sharon, Howard Streicher, Rebecca A Enos, Melissa D Bowman, Valerie M Tatard-Leitman, Beatriz Sanchez-Espiridion, Srinika Ranasinghe, Mina Pichavant, Diane M Del Valle, Joyce Yu, Sylvie Janssens, Jenny Peterson-Klaus, Cathy Rowe, Gerold Bongers, Robert R Jenq, Chia-Chi Chang, Jeffrey S Abrams, Margaret Mooney, James H Doroshow, Lyndsay N Harris, Magdalena Thurin,

<h4>Purpose</h4>Immunoprofiling to identify biomarkers and integration with clinical trial outcomes are critical to improving immunotherapy approaches for patients with cancer. However, the translational potential of individual studies is often limited by small sample size of trials and the complexity of immuno-oncology biomarkers. Variability in assay performance further limits comparison and ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(18):5038-5048]

Cited: 0 times

View full text PDF listing >>

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.

, Jens D Lundgren, Birgit Grund, Christina E Barkauskas, Thomas L Holland, Robert L Gottlieb, Uriel Sandkovsky, Samuel M Brown, Kirk U Knowlton, Wesley H Self, D Clark Files, Mamta K Jain, Thomas Benfield, Michael E Bowdish, Bradley G Leshnower, Jason V Baker, Jens-Ulrik Jensen, Edward M Gardner, Adit A Ginde, Estelle S Harris, Isik S Johansen, Norman Markowitz, Michael A Matthay, Lars Østergaard, Christina C Chang, Victoria J Davey, Anna Goodman, Elizabeth S Higgs, Daniel D Murray, Thomas A Murray, Roger Paredes, Mahesh K B Parmar, Andrew N Phillips, Cavan Reilly, Shweta Sharma, Robin L Dewar, Marc Teitelbaum, Deborah Wentworth, Huyen Cao, Paul Klekotka, Abdel G Babiker, Annetine C Gelijns, Virginia L Kan, Mark N Polizzotto, B Taylor Thompson, H Clifford Lane, James D Neaton,

<h4>Background</h4>LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19.<h4>Methods</h4>In this platform trial of ... Read more >>

N Engl J Med (The New England journal of medicine)
[2021, 384(10):905-914]

Cited: 76 times

View full text PDF listing >>

Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.

Michael L Maitland, Julia Wilkerson, Sanja Karovic, Binsheng Zhao, Jessica Flynn, Mengxi Zhou, Patrick Hilden, Firas S Ahmed, Laurent Dercle, Chaya S Moskowitz, Ying Tang, Dana E Connors, Stacey J Adam, Gary Kelloff, Mithat Gonen, Tito Fojo, Lawrence H Schwartz, Geoffrey R Oxnard,

<h4>Purpose</h4>Mathematical models combined with new imaging technologies could improve clinical oncology studies. To improve detection of therapeutic effect in patients with cancer, we assessed volumetric measurement of target lesions to estimate the rates of exponential tumor growth and regression as treatment is administered.<h4>Experimental design</h4>Two completed phase III trials were studied ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(24):6464-6474]

Cited: 0 times

View full text PDF listing >>

MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC.

Renumathy Dhanasekaran, Jangho Park, Alekesey Yevtodiyenko, David I Bellovin, Stacey J Adam, Anand Rajan Kd, Meital Gabay, Hanan Fernando, Julia Arzeno, Vinodhini Arjunan, Sergei Gryanzov, Dean W Felsher,

The MYC oncogene is dysregulated in most human cancers and hence is an attractive target for cancer therapy. We and others have shown experimentally in conditional transgenic mouse models that suppression of the MYC oncogene is sufficient to induce rapid and sustained tumor regression, a phenomenon known as oncogene addiction. ... Read more >>

Mol Ther Nucleic Acids (Molecular therapy. Nucleic acids)
[2020, 21:850-859]

Cited: 3 times

View full text PDF listing >>

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

Laurent Dercle, Dana E Connors, Ying Tang, Stacey J Adam, Mithat Gönen, Patrick Hilden, Sanja Karovic, Michael Maitland, Chaya S Moskowitz, Gary Kelloff, Binsheng Zhao, Geoffrey R Oxnard, Lawrence H Schwartz,

<h4>Purpose</h4>To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors.<h4>Patients and methods</h4>The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable ... Read more >>

JCO Clin Cancer Inform (JCO clinical cancer informatics)
[2018, 2:1-12]

Cited: 3 times

View full text PDF listing >>

p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.

Alper Yetil, Benedict Anchang, Arvin M Gouw, Stacey J Adam, Tahera Zabuawala, Ramya Parameswaran, Jan van Riggelen, Sylvia Plevritis, Dean W Felsher,

MYC-induced T-ALL exhibit oncogene addiction. Addiction to MYC is a consequence of both cell-autonomous mechanisms, such as proliferative arrest, cellular senescence, and apoptosis, as well as non-cell autonomous mechanisms, such as shutdown of angiogenesis, and recruitment of immune effectors. Here, we show, using transgenic mouse models of MYC-induced T-ALL, that ... Read more >>

Oncotarget (Oncotarget)
[2015, 6(6):3563-3577]

Cited: 9 times

View full text PDF listing >>

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.

Emelyn H Shroff, Livia S Eberlin, Vanessa M Dang, Arvin M Gouw, Meital Gabay, Stacey J Adam, David I Bellovin, Phuoc T Tran, William M Philbrick, Adolfo Garcia-Ocana, Stephanie C Casey, Yulin Li, Chi V Dang, Richard N Zare, Dean W Felsher,

The MYC oncogene is frequently mutated and overexpressed in human renal cell carcinoma (RCC). However, there have been no studies on the causative role of MYC or any other oncogene in the initiation or maintenance of kidney tumorigenesis. Here, we show through a conditional transgenic mouse model that the MYC ... Read more >>

Proc Natl Acad Sci U S A (Proceedings of the National Academy of Sciences of the United States of America)
[2015, 112(21):6539-6544]

Cited: 98 times

View full text PDF listing >>

Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.

Phuoc T Tran, Emelyn H Shroff, Timothy F Burns, Saravanan Thiyagarajan, Sandhya T Das, Tahera Zabuawala, Joy Chen, Yoon-Jae Cho, Richard Luong, Pablo Tamayo, Tarek Salih, Khaled Aziz, Stacey J Adam, Silvestre Vicent, Carsten H Nielsen, Nadia Withofs, Alejandro Sweet-Cordero, Sanjiv S Gambhir, Charles M Rudin, Dean W Felsher,

KRAS mutant lung cancers are generally refractory to chemotherapy as well targeted agents. To date, the identification of drugs to therapeutically inhibit K-RAS have been unsuccessful, suggesting that other approaches are required. We demonstrate in both a novel transgenic mutant Kras lung cancer mouse model and in human lung tumors ... Read more >>

PLoS Genet (PLoS genetics)
[2012, 8(5):e1002650]

Cited: 63 times

View full text PDF listing >>

Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.

Peter S Choi, Jan van Riggelen, Andrew J Gentles, Pavan Bachireddy, Kavya Rakhra, Stacey J Adam, Sylvia K Plevritis, Dean W Felsher,

The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction. However, after prolonged inactivation of MYC in a conditional transgenic mouse model of Eμ-tTA/tetO-MYC T-cell acute lymphoblastic leukemia, some of the ... Read more >>

Proc Natl Acad Sci U S A (Proceedings of the National Academy of Sciences of the United States of America)
[2011, 108(42):17432-17437]

Cited: 24 times

View full text PDF listing >>

Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.

Sarasija Naini, Katherine T Etheridge, Stacey J Adam, Stephen J Qualman, Rex C Bentley, Christopher M Counter, Corinne M Linardic,

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Despite advances in therapy, patients with a histologic variant of RMS known as alveolar (aRMS) have a 5-year survival rate of <30%. aRMS tissues exhibit a number of genetic changes, including loss-of-function of the p53 and Rb ... Read more >>

Cancer Res (Cancer research)
[2008, 68(23):9583-9588]

Cited: 47 times

View full text PDF listing >>

A method to generate genetically defined tumors in pigs.

Stacey J Adam, Christopher M Counter,

As a biomedical model, pigs offer many advantages and hence have been utilized extensively for toxicology, Crohn's disease, diabetes, and organ transplantation, as well as many other research areas. However, the advantages of porcine models, particularly its large size and similarity to humans, were not exploited previously to any large ... Read more >>

Methods Enzymol (Methods in enzymology)
[2008, 439:39-51]

Cited: 7 times

View full text PDF listing >>

Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.

Kian-Huat Lim, Kevin O'Hayer, Stacey J Adam, S Disean Kendall, Paul M Campbell, Channing J Der, Christopher M Counter,

<h4>Background</h4>The Ral guanine nucleotide-exchange factors (RalGEFs) serve as key effectors for Ras oncogene transformation of immortalized human cells. RalGEFs are activators of the highly related RalA and RalB small GTPases, although only the former has been found to promote Ras-mediated growth transformation of human cells. In the present study, we ... Read more >>

Curr Biol (Current biology : CB)
[2006, 16(24):2385-2394]

Cited: 144 times

View full text PDF listing >>

Genetically engineered human cancer models utilizing mammalian transgene expression.

S DiSean Kendall, Stacey J Adam, Christopher M Counter,

Cancer models are vital to cancer biology research, and multiple cancer models are currently available that utilize either murine or human cells, each with particular strengths and weaknesses. The ability to transform primary human cells into tumors through the expression of specific transgenes offers many advantages as a cancer model, ... Read more >>

Cell Cycle (Cell cycle (Georgetown, Tex.))
[2006, 5(10):1074-1079]

Cited: 17 times

View full text PDF listing >>

A network of genetic events sufficient to convert normal human cells to a tumorigenic state.

S DiSean Kendall, Corinne M Linardic, Stacey J Adam, Christopher M Counter,

Although great progress has been made at identifying and characterizing individual genes involved in cancer, less is known about how the combination of such genes collaborate to form tumors in humans. To this end, we sought to genetically recreate tumorigenesis in normal human cells using genes altered in human cancer. ... Read more >>

Cancer Res (Cancer research)
[2005, 65(21):9824-9828]

Cited: 60 times

View full text PDF listing >>

Alpha7 nicotinic acetylcholine receptors targeted by cholinergic developmental neurotoxicants: nicotine and chlorpyrifos.

Theodore A Slotkin, Matthew C Southard, Stacey J Adam, Mandy M Cousins, Frederic J Seidler,

Alpha7 nicotinic acetylcholine receptors (nAChRs) play a role in axonogenesis, synaptogenesis and synaptic plasticity, and are therefore potential targets for developmental neurotoxicants. We administered nicotine to neonatal rats during discrete periods spanning the onset and peak of axonogenesis/synaptogenesis, focusing on three brain regions with disparate distributions of cell bodies and ... Read more >>

Brain Res Bull (Brain research bulletin)
[2004, 64(3):227-235]

Cited: 23 times

View full text PDF listing >>



1.239 s